Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
IGM Biosciences ( (IGMS) ) just unveiled an update.
IGM Biosciences announced a strategic update to halt the development of two antibody therapies, imvotamab and IGM-2644, for autoimmune diseases due to insufficient results and strategic considerations. As part of the restructuring, the company will reduce its workforce by 73% to preserve cash and is exploring internal and strategic alternatives to maximize shareholder value.
More about IGM Biosciences
IGM Biosciences is a biotechnology company focused on developing and delivering medicines for autoimmune and inflammatory diseases. They have a collaboration agreement with Sanofi to develop IgM antibody agonists targeting immunology and inflammation.
YTD Price Performance: -0.16%
Average Trading Volume: 231,392
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $368.7M
For an in-depth examination of IGMS stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue